The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
This under-the-radar hospitality stock boasts a Superscore of 79 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.
Firefly's hypergrowth masks massive cash burn, while Rocket Lab trades at a premium despite better financial discipline. One valuation gap may matter more than you think.
This AI networking specialist is growing like a weed, but its future rests on a handful of very big customers. Here's what the next three years could bring.
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Ward's purchase through his revocable trust brings his aggregate stake to 28.4 million units, representing a 17.0% ownership interest in the energy partnership.
iShares Silver Trust offers lower fees and $30.5B in assets, while Global X Silver Miners ETF delivers dividend income and operational leverage from mining companies.
CrowdStrike trades at a steep premium despite ongoing profitability challenges, while UiPath has just turned profitable with a valuation multiple a fraction of its rival's.
AMD's net margin doubled while Qualcomm trades at a fraction of its rival's valuation, but customer concentration and competitive threats complicate both bets.
SoundHound's story has changed. The next few quarters should reveal whether its expanded platform can convert greater customer reach into durable growth and stronger economics.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
